118 related articles for article (PubMed ID: 35104671)
1. Combinatorial cetuximab targeted polymeric nanocomplexes reduce PRC1 level and abrogate growth of metastatic hepatocellular carcinoma in vivo with efficient radionuclide uptake.
Poojari R; Mohanty B; Kadwad V; Suryawanshi D; Chaudhari P; Khade B; Srivastava R; Gupta S; Panda D
Nanomedicine; 2022 Apr; 41():102529. PubMed ID: 35104671
[TBL] [Abstract][Full Text] [Related]
2. A Chimeric Cetuximab-Functionalized Corona as a Potent Delivery System for Microtubule-Destabilizing Nanocomplexes to Hepatocellular Carcinoma Cells: A Focus on EGFR and Tubulin Intracellular Dynamics.
Poojari R; Kini S; Srivastava R; Panda D
Mol Pharm; 2015 Nov; 12(11):3908-23. PubMed ID: 26426829
[TBL] [Abstract][Full Text] [Related]
3. Co-administration of combretastatin A4 nanoparticles and anti-PD-L1 for synergistic therapy of hepatocellular carcinoma.
Zhao B; Dong Z; Liu W; Lou F; Wang Q; Hong H; Wang Y
J Nanobiotechnology; 2021 May; 19(1):124. PubMed ID: 33933077
[TBL] [Abstract][Full Text] [Related]
4. Glycyrrhetinic Acid-Mediated Polymeric Drug Delivery Targeting the Acidic Microenvironment of Hepatocellular Carcinoma.
Zhang J; Zhang M; Ji J; Fang X; Pan X; Wang Y; Wu C; Chen M
Pharm Res; 2015 Oct; 32(10):3376-90. PubMed ID: 26148773
[TBL] [Abstract][Full Text] [Related]
5. Distinct stratification of normal liver, hepatocellular carcinoma (HCC), and anticancer nanomedicine-treated- tumor tissues by Raman fingerprinting for HCC therapeutic monitoring.
Poojari R; Bhujbal M; Hole A; Murali Krishna C
Nanomedicine; 2021 Apr; 33():102352. PubMed ID: 33418135
[TBL] [Abstract][Full Text] [Related]
6. Co-administration of combretastatin A4 nanoparticles and sorafenib for systemic therapy of hepatocellular carcinoma.
Wang Y; Yu H; Zhang D; Wang G; Song W; Liu Y; Ma S; Tang Z; Liu Z; Sakurai K; Chen X
Acta Biomater; 2019 Jul; 92():229-240. PubMed ID: 31100462
[TBL] [Abstract][Full Text] [Related]
7. Albumin-Embellished Arsenic Trioxide-Loaded Polymeric Nanoparticles Enhance Tumor Accumulation and Anticancer Efficacy via Transcytosis for Hepatocellular Carcinoma Therapy.
Huang Y; Xu Z; Wei Y; Han S; Cai X; Chen D
AAPS PharmSciTech; 2022 Apr; 23(4):111. PubMed ID: 35411416
[TBL] [Abstract][Full Text] [Related]
8. Co-delivery of sorafenib and metapristone encapsulated by CXCR4-targeted PLGA-PEG nanoparticles overcomes hepatocellular carcinoma resistance to sorafenib.
Zheng N; Liu W; Li B; Nie H; Liu J; Cheng Y; Wang J; Dong H; Jia L
J Exp Clin Cancer Res; 2019 May; 38(1):232. PubMed ID: 31151472
[TBL] [Abstract][Full Text] [Related]
9. SP94 Peptide-Functionalized PEG-PLGA Nanoparticle Loading with Cryptotanshinone for Targeting Therapy of Hepatocellular Carcinoma.
Nie X; Liu Y; Li M; Yu X; Yuan W; Huang S; Ren D; Wang Y; Wang Y
AAPS PharmSciTech; 2020 Apr; 21(4):124. PubMed ID: 32342227
[TBL] [Abstract][Full Text] [Related]
10. Cetuximab-conjugated PLGA nanoparticles as a prospective targeting therapeutics for non-small cell lung cancer.
Kumari L; Ehsan I; Mondal A; Al Hoque A; Mukherjee B; Choudhury P; Sengupta A; Sen R; Ghosh P
J Drug Target; 2023 Jun; 31(5):521-536. PubMed ID: 37010248
[TBL] [Abstract][Full Text] [Related]
11. Targeted hepatocellular carcinoma therapy: transferrin modified, self-assembled polymeric nanomedicine for co-delivery of cisplatin and doxorubicin.
Zhang X; Li J; Yan M
Drug Dev Ind Pharm; 2016 Oct; 42(10):1590-9. PubMed ID: 26942448
[TBL] [Abstract][Full Text] [Related]
12. Enhanced anti-PD-1 therapy in hepatocellular carcinoma by tumor vascular disruption and normalization dependent on combretastatin A4 nanoparticles and DC101.
Bao X; Shen N; Lou Y; Yu H; Wang Y; Liu L; Tang Z; Chen X
Theranostics; 2021; 11(12):5955-5969. PubMed ID: 33897892
[TBL] [Abstract][Full Text] [Related]
13. Delivery of melarsoprol using folate-targeted PEGylated cyclodextrin-based nanoparticles for hepatocellular carcinoma.
Li YN; Shi X; Sun D; Han S; Zou Y; Wang L; Yang L; Li Y; Shi Y; Guo J; O'Driscoll CM
Int J Pharm; 2023 Apr; 636():122791. PubMed ID: 36863541
[TBL] [Abstract][Full Text] [Related]
14. Improved therapeutic effect of DOX-PLGA-PEG micelles decorated with bivalent fragment HAb18 F(ab')(2) for hepatocellular carcinoma.
Jin C; Qian N; Zhao W; Yang W; Bai L; Wu H; Wang M; Song W; Dou K
Biomacromolecules; 2010 Sep; 11(9):2422-31. PubMed ID: 20831277
[TBL] [Abstract][Full Text] [Related]
15. Stepwise pH-responsive nanoparticles containing charge-reversible pullulan-based shells and poly(β-amino ester)/poly(lactic-co-glycolic acid) cores as carriers of anticancer drugs for combination therapy on hepatocellular carcinoma.
Zhang C; An T; Wang D; Wan G; Zhang M; Wang H; Zhang S; Li R; Yang X; Wang Y
J Control Release; 2016 Mar; 226():193-204. PubMed ID: 26896737
[TBL] [Abstract][Full Text] [Related]
16. Low-toxicity transferrin-guided polymersomal doxorubicin for potent chemotherapy of orthotopic hepatocellular carcinoma in vivo.
Wei Y; Gu X; Cheng L; Meng F; Storm G; Zhong Z
Acta Biomater; 2019 Jul; 92():196-204. PubMed ID: 31102765
[TBL] [Abstract][Full Text] [Related]
17. iRGD-Decorated Polymeric Nanoparticles for the Efficient Delivery of Vandetanib to Hepatocellular Carcinoma: Preparation and in Vitro and in Vivo Evaluation.
Wang J; Wang H; Li J; Liu Z; Xie H; Wei X; Lu D; Zhuang R; Xu X; Zheng S
ACS Appl Mater Interfaces; 2016 Aug; 8(30):19228-37. PubMed ID: 27381493
[TBL] [Abstract][Full Text] [Related]
18. Anti-GPC3 antibody-modified sorafenib-loaded nanoparticles significantly inhibited HepG2 hepatocellular carcinoma.
Tang X; Chen L; Li A; Cai S; Zhang Y; Liu X; Jiang Z; Liu X; Liang Y; Ma D
Drug Deliv; 2018 Nov; 25(1):1484-1494. PubMed ID: 29916268
[TBL] [Abstract][Full Text] [Related]
19. Fabrication, optimization, and characterization of umbelliferone β-D-galactopyranoside-loaded PLGA nanoparticles in treatment of hepatocellular carcinoma: in vitro and in vivo studies.
Kumar V; Bhatt PC; Rahman M; Kaithwas G; Choudhry H; Al-Abbasi FA; Anwar F; Verma A
Int J Nanomedicine; 2017; 12():6747-6758. PubMed ID: 28932118
[TBL] [Abstract][Full Text] [Related]
20. Glycyrrhetinic acid-decorated and reduction-sensitive micelles to enhance the bioavailability and anti-hepatocellular carcinoma efficacy of tanshinone IIA.
Chen F; Zhang J; He Y; Fang X; Wang Y; Chen M
Biomater Sci; 2016 Jan; 4(1):167-82. PubMed ID: 26484363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
